Vardenafil (levitra): new aspects of clinical efficacy


Cite item

Full Text

Abstract

Vardenafil (levitra, Bayer Schering Pharna, Germany) is a 5-phosphodiesterase inhibitor which proved highly effective and safe in the treatment of erectile dysfunction. Special techniques were used to study sexual satisfaction of female partners of men treated with vardenafil. It was found that vardenafil raises significantly sexual satisfaction of female partners of men treated with vardenafil and prolongs erection. This is a new aspect of vardenafil efficacy.

References

  1. Francis S. H., Corbin J. D. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr. Urol. Rep. 2003; 4: 457-465.
  2. Rotella D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 2002; 1: 674-682.
  3. Montorsi F., Salonia A., Briganti A. et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur. Urol. 2005; 47: 612-621.
  4. Nehra A., Grantmyre J., Nadel A. et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. (Baltimore). J. Urol. 2005; 173: 2067-2071.
  5. Goldstein I., Young J. M., Fischer J. et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabet. Care. 2003; 26: 777-783.
  6. Wagner G., Fugl-Meyer K. S., Fugl-Meyer A. R. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int. J. Impot. Res. 2000; 12 (Suppl. 4): S144-S146.
  7. Chevret M., Jaudinot E., Sullivan K. et al. Impact of erectile dysfunction (ED) on sexual life of female partners: assessment with the Index of Sexual Life (ISL) questionnaire. J. Sex. Marital. Ther. 2004; 30: 157-172.
  8. Fisher W. A., Rosen R. C., Eardley I. et al. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J. Sex. Med. 2005; 2: 675-684.
  9. Rosen R. C., Fisher W. A., Beneke M. et al. The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment. Br. J. Urol. Int. 2007; 99: 849-859.
  10. Weiss P., Brody S. Women's partnered orgasm consistency is associated with greater duration of penile-vaginal intercourse but not of foreplay. J. Sex. Med. 2009; 6: 135-141.
  11. Miller S. A., Byers E. S. Actual and desired duration of foreplay and intercourse: discordance and misperceptions within heterosexual couples. J. Sex. Res. 2004; 41: 301-309.
  12. Rosenberg M. T., Adams P. L., McBride T. A. et al. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int. J. Clin. Pract. 2009; 63: 27-34.
  13. Miner M., Gilderman L., Bailen J. et al. Vardenafil in men with stable statin therapy and dyslipidemia. J. Sex. Med. 2008; 5: 1455-1467.
  14. Мазо Е. Б., Гамидов С. И., Иремашвили В. В., Гасанов Р. В. Патогенез эректильной дисфункции при метаболическом синдроме. Вестн. РАМН 2008; 2: 21-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies